XXXX in outpatients with stable @entity453 - results from multicenter RECENT study.

@entity1 @entity712 @entity955 @entity453 @entity943 @entity65
UNASSIGNED: INTRODUCTION @entity955 ( @entity955 ) frequently coexists with other @entity65 . OBJECTIVES The aim of this study was to assess the prevalence of @entity955 in outpatients with stable @entity453 ( @entity453 ), and to determine clinical and laboratory correlates of this @entity943 . Further, we compared the indications for antithrombotic therapy using the older CHADS2 and the modern CHA2DS2-VASc score. @entity1 AND METHODS We investigated a representative sample of 2578 Polish @entity1 with stable @entity453 participating in the multicenter RECENT study (age: 65  10 years; @entity1 : 55%; CCS class I/II/III+IV: 38/48/14%). RESULTS @entity955 was present in 19% of @entity1 with @entity453 . Advanced age, the longer history of @entity453 , and concomitant @entity712 were independently associated with the higher prevalence of @entity955 (all P<0.05). Among @entity1 with @entity453 and @entity955 , according to the CHADS2 score 73% of subjects required antithrombotic therapy (score >= 2) and according to the CHA2DS2-VASc score - 94% (score >= 2). 47% of @entity1 with the CHADS2 score of 0 and 85% with the CHADS2 score of 1 had the CHA2DS2-VASc score >= 2. Therefore, 21% of @entity1 with @entity453 and @entity955 did not have strong indications for antithrombotic therapy according to the CHADS2 score (0-1), while they required oral anticoagulation based on the CHA2DS2-VASc score (>= 2). CONCLUSIONS @entity955 affects every fifth @entity453 @entity1 . According to CHA2DS2-VASc score almost all @entity1 with @entity453 and @entity955 require antithrombotic management, which can complicate coronary revascularization and make the related antiplatelet therapy challenging.
